<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Lemborexant" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Lemborexant</book-part-id>
      <title-group>
        <title>Lemborexant</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>2</month>
          <year>2025</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Leflunomide" document-type="chapter">Leflunomide</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="LemonBalm" document-type="chapter">Lemon Balm</related-object>
    </book-part-meta>
    <body>
      <sec id="Lemborexant.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Lemborexant.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Lemborexant is an orexin receptor antagonist used for the treatment of insomnia and sleep disorders. Lemborexant therapy is associated with rare occurrence of transient serum enzyme elevations but has not been implicated in cases of clinically apparent liver injury.</p>
        </sec>
        <sec id="Lemborexant.Background">
          <title>Background</title>
          <p>Lemborexant (lem&#x0201d; boe rex' ant) is an orexin receptor antagonist which is used to treat insomnia. Central nervous system neurons with orexin receptors are involved in wakefulness and are inactive during sleep. Engagement of the orexin receptor results in wakefulness, and loss of the receptor can result in excessive daytime sleepiness and narcolepsy. Inhibition of orexin receptor signaling using lemborexant has been shown to shorten the time to falling asleep and to prolong sleep in patients with sleep-onset and sleep-maintenance insomnia. Lemborexant was approved for use in the United States in 2019, the second such orexin based drug approved for chronic insomnia (the first being suvorexant). Lemborexant is available in tablets of 5 and 10 mg under the brand name Dayvigo. The recommended dose is 5 mg taken orally within 30 minutes of bedtime. The dose can be increased to 10 mg. Side effects are few, but may include daytime somnolence, fatigue, dizziness, headache and vivid or abnormal dreams. Rare side effects include sleep paralysis, cataplexy, nightmares, excessive daytime sleepiness, worsening of depression and suicidal ideation and behaviors. Lemborexant can also decrease respiratory function and should be used with caution in persons with respiratory illnesses. Lemborexant, like other orexin antagonists, is classified as a Schedule 4 controlled substance, meaning that it has a low potential for abuse or dependence but has an approved medical use.</p>
        </sec>
        <sec id="Lemborexant.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In several clinical trials, lemborexant was found to be well tolerated, with serum ALT elevations above 3 times the upper limit of normal in less than 1% of treated subjects and with similar rates in placebo recipients. The elevations were transient and asymptomatic, none required dose modification or discontinuation, and none were associated with a simultaneous elevation in serum bilirubin. Thus, in the registration trials of lemborexant, there were no reports of clinically apparent liver injury. Since its approval and more widespread use, lemborexant has been available has not been implicated in causing cases of clinically apparent liver injury.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Lemborexant.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism by which lemborexant might cause liver injury is unknown. Lemborexant is metabolized by the cytochrome P450 system (predominantly CYP3A4) and the dose may need to be altered in patients taking strong inhibitors (decreasing dose) or inducers (increasing dose) of the enzymes. The relative lack of serious liver related adverse events is probably due to the low doses used and its uncommon, intermittent use.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="Sedatives_Hypnotics" document-type="book-part">Sedatives and Hypnotics</related-object>, Drugs for Insomnia</p>
          <p>Other Orexin Receptor Antagonists: <related-object link-type="booklink" source-id="livertox" document-id="Daridorexant" document-type="book-part">Daridorexant</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Suvorexant" document-type="book-part">Suvorexant</related-object></p>
        </sec>
      </sec>
      <sec id="Lemborexant.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Lemborexant &#x02013; Dayvigo&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Sedatives and Hypnotics</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Lemborexant">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Lemborexant.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Lemborexant.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Lemborexant.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Lemborexant.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO</th>
                <th id="hd_h_Lemborexant.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Lemborexant.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Lemborexant.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Lemborexant</td>
                <td headers="hd_h_Lemborexant.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://223370430">1369764-02-2</ext-link>
</td>
                <td headers="hd_h_Lemborexant.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C22-H20-F2-N4-O2</td>
                <td headers="hd_h_Lemborexant.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="223370430" document-id-type="sid" document-type="summary" object-id="223370430" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Lemborexant.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 5 February 2025</p>
        <ref-list id="Lemborexant.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Lemborexant.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Unconventional drugs. Miscellaneous drugs and diagnostic chemicals. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 731-4.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999; lemborexant and the orexin receptor antagonists are not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.larrey.2013">
            <mixed-citation publication-type="book">Larrey D, Ripault MP. Anxiolytic agents. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, p. 455-6.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of hypnotics and sedatives discusses benzodiazepines, buspirone and valerian, all of which have been linked to rare cases of liver injury; suvorexant and orexin receptor antagonists are not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.mihic.2018">
            <mixed-citation publication-type="book">Mihic SJ, Mayfield J, Harris RA. Hypnotics and sedatives. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 339-354.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics discusses suvorexant but not lemborexant).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.multidiscipline_review.2019">
            <mixed-citation publication-type="web"><string-name name-style="western"><given-names>FDA.</given-names>
<surname>Multi-Discipline Review</surname></string-name>. <year>2019</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf</ext-link><annotation><p><italic toggle="yes">(FDA website with product labels and multiple disciplinary reviews that supported approval of lemborexant in the US, mentions that there were no deaths, no evidence of abuse or diversion, no hepatic serious adverse events, no discontinuations for hepatic events, and no significant shift or change in serum enzyme levels during therapy, no instance of ALT elevation with jaundice, and in registration trials, ALT elevations of more than 3 times ULN arose in 0.6% of lemborexant and 0.6% of placebo recipients).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.chalasani.2015.1340">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chalasani</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bonkovsky</surname>
<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stolz</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Talwalkar</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname>
<given-names>KR</given-names></string-name>, <etal>et al.</etal>; <collab>United States Drug Induced Liver Injury Network</collab>. <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
<source>Gastroenterology</source>
<year>2015</year>; <volume>148</volume>: <fpage seq="b">1340</fpage>-<lpage>52.e7</lpage>.<annotation><p><italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 82 [9%] were attributed to agents active in the central nervous system, but none were sedatives or sleeping aids).</italic></p></annotation><pub-id pub-id-type="pmid">25754159</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF6">
            <mixed-citation publication-type="journal"><article-title>Drugs for insomnia.</article-title>
<source>Med Lett Drugs Ther</source>
<year>2015</year>; <volume>57</volume>(<issue>1472</issue>): <fpage>95</fpage>-<lpage>8</lpage>.<annotation><p><italic toggle="yes">(Concise review of the mechanism of action, efficacy, safety and costs of drugs for insomnia including benzodiazepine receptor agonists, benzodiazepines, melatonin receptor agonists, orexin receptor antagonists such as suvorexant and other agents including nonprescription and herbal products; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">26147892</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.murphy.2017.1289">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Murphy</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Moline</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mayleben</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zammit</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pinner</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Dhadda</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Lemborexant, a dual orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a Bayesian, adaptive, randomized, double-blind, placebo-controlled study.</article-title>
<source>J Clin Sleep Med.</source>
<year>2017</year>;<volume>13</volume>: <fpage>1289</fpage>-<lpage>1299</lpage>.<annotation><p><italic toggle="yes">(Among 291 adults with insomnia treated with lemborexant [1, 2.5, 5, 10, 15 or 25 mg] vs placebo once nightly for 15 days, doses of 2.5 to 10 mg yielded the optimal balance of efficacy vs next morning residual sleepiness [~3% vs 22% at highest doses], and there were &#x0201c;no clinically important differences&#x0201d; between drug and placebo treatment in blood chemistry results).</italic></p></annotation><pub-id pub-id-type="pmid">29065953</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.rosenberg.2019.e1918254">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Rosenberg</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zammit</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mayleben</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dhadda</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Filippov</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal>
<article-title>Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial.</article-title>
<source>JAMA Netw Open.</source>
<year>2019</year>;<volume>2</volume>:<elocation-id>e1918254</elocation-id>.<annotation><p><italic toggle="yes">(Among 1006 older adults with insomnia, treated with study drugs once nightly for 1 month, time to sleep onset and sleep maintenance were improved more with lemborexant [5 or 10 mg] than zolpidem or placebo, and adverse events were largely mild-to-moderate, with no treatment related serious adverse events, no deaths and &#x0201c;no notable findings were reported for clinical laboratory tests&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">31880796</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.scott.2020.425">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Scott</surname>
<given-names>LJ</given-names></string-name>. <article-title>Lemborexant: first approval.</article-title>
<source>Drugs.</source>
<year>2020</year>;<volume>80</volume>:<fpage>425</fpage>-<lpage>432</lpage>.<annotation><p><italic toggle="yes">(Review of the mechanism of action, history of development, pharmacology, clinical efficacy and safety of lemborexant, shortly after its approval for treatment of insomnia in the US, does not mention ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">32096020</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF10">
            <mixed-citation publication-type="journal"><article-title>Lemborexant (Dayvigo) for insomnia.</article-title>
<source>Med Lett Drugs Ther.</source>
<year>2020</year>;<volume>62</volume>(<issue>1601</issue>):<fpage>97</fpage>-<lpage>100</lpage>.<annotation><p><italic toggle="yes">(Concise review of the mechanism of action, clinical efficacy, safety and costs of lemborexant, mentions side effects of somnolence, headaches, abnormal dreams, depression, suicidal ideation and sleep paralysis and cataplexy, but no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">32724021</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.k_rpp_.2020.zsaa123">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>K&#x000e4;rpp&#x000e4;</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yardley</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pinner</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Filippov</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zammit</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Moline</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Perdomo</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal>
<article-title>Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.</article-title>
<source>Sleep.</source>
<year>2020</year>;<volume>43</volume>:<elocation-id>zsaa123</elocation-id>.<annotation><p><italic toggle="yes">(Among 949 adults with insomnia treated with lemborexant [5 or 10 mg] vs placebo for 6 months, improvements in time to sleep onset and sleep maintenance were greater with lemborexant and overall adverse event rates were similar, except for somnolence [4.1% and 8.6% vs 1.6%] and fatigue [3.8% and 3.5% vs 0.3%], and there were &#x0201c;no clinically important mean changes in &#x02026; chemistry laboratory parameters&#x0201d; while the incidence of abnormal values was low and similar in the three groups).</italic></p></annotation><pub-id pub-id-type="pmid">32585700</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.muehlan.2020.1063">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Muehlan</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vaillant</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zenklusen</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kraehenbuehl</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dingemanse</surname>
<given-names>J</given-names></string-name>. <article-title>Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders.</article-title>
<source>Expert Opin Drug Metab Toxicol.</source>
<year>2020</year>;<volume>16</volume>:<fpage>1063</fpage>-<lpage>1078</lpage>.<annotation><p><italic toggle="yes">(Review of the role of orexin in sleep and wakefulness, and the mechanism of action, pharmacology, clinical efficacy and safety of orexin receptor antagonists including suvo-, lembo-, darido- and seltorexant, all of which have similar side effects but are generally &#x0201c;well tolerated&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">32901578</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.moline.2021.7">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Moline</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Thein</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bsharat</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rabbee</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kemethofer-Waliczky</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Filippov</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Kubota</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>Safety and efficacy of lemborexant in patients with irregular sleep-wake rhythm disorder and Alzheimer's disease dementia: results from a phase 2 randomized clinical trial.</article-title>
<source>J Prev Alzheimers Dis.</source>
<year>2021</year>;<volume>8</volume>:<fpage>7</fpage>-<lpage>18</lpage>.<annotation><p><italic toggle="yes">(Among 62 adults with Alzheimer disease and irregular sleep-wake rhythm disorder treated with lemborexant [2.5, 5, 10 or 15 mg] vs placebo for 4 weeks, measures of restlessness and circadian rhythm variables improved with lemborexant, and there were no serious adverse events or treatment related adverse events leading to discontinuation; no mention of ALT or laboratory test results).</italic></p></annotation><pub-id pub-id-type="pmid">33336219</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.yardley.2021.333">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Yardley</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>K&#x000e4;rpp&#x000e4;</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Inoue</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Pinner</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Perdomo</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ishikawa</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Filippov</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal>
<article-title>Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.</article-title>
<source>Sleep Med.</source>
<year>2021</year>;<volume>80</volume>:<fpage>333</fpage>-<lpage>342</lpage>.<annotation><p><italic toggle="yes">(Among 949 adults with insomnia enrolled in a randomized, placebo-control trial of lemborexant for 6 months followed by open label drug for a total of 12 months, improvements in time to sleep onset, sleep maintenance and self-reported sleep quality were maintained, adverse event rates tended to decrease with continued therapy, and &#x0201c;there were no clinically significant findings for any&#x02026;chemistry laboratory parameter&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">33636648</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.preskorn.2023.38">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Preskorn</surname>
<given-names>SH</given-names></string-name>. <article-title>Comparative pharmacology of the 3 marketed dual orexin antagonists-daridorexant, lemborexant, and suvorexant-part 2. principal drug metabolizing enzyme, drug-drug interactions, and effects of liver and renal impairment on metabolism.</article-title>
<source>J Psychiatr Pract.</source>
<year>2023</year>;<volume>29</volume>:<fpage>38</fpage>-<lpage>41</lpage>.<annotation><p><italic toggle="yes">(Review of the pharmacokinetics of the 3 orexin antagonists in clinical use, including suvo-, lembo-, and daridorexant, mentions that they have similar chemical structures and similar metabolism by CYP 3A4, with only minor differences in susceptibility to inducers and inhibitors of CYP 3A4).</italic></p></annotation><pub-id pub-id-type="pmid">36649550</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF16">
            <mixed-citation publication-type="journal"><article-title>Drugs for chronic insomnia.</article-title>
<source>Med Lett Drugs Ther.</source>
<year>2023</year>;<volume>65</volume>:<fpage>1</fpage>-<lpage>6</lpage>.<annotation><p><italic toggle="yes">(Concise description of drugs approved for use in chronic insomnia including relative efficacy, safety and costs, mentions that orexin receptor inhibitors improve latency to falling asleep by 5-10 minutes and duration of sleep to waking by 15-25 minutes compared to placebo and that the most common adverse events are somnolence, fatigue, headache, and abnormal dreams; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">36630579</pub-id>
</mixed-citation>
          </ref>
          <ref id="Lemborexant.REF.pan.2023.587">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pan</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>
<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal>
<article-title>The comparative effectiveness and safety of insomnia drugs: a systematic review and network meta-analysis of 153 randomized trials.</article-title>
<source>Drugs.</source>
<year>2023</year>;<volume>83</volume>:<fpage>587</fpage>-<lpage>619</lpage>.<annotation><p><italic toggle="yes">(Systematic review of the literature on the safety of drugs for insomnia identified 61 trials with 25,093 patients, and while the frequency of common adverse events varied, &#x0201c;with respect to serious and drug-related adverse events, there were no differences among the drugs&#x02019;; no mention of liver related adverse events).</italic></p></annotation><pub-id pub-id-type="pmid">36947394</pub-id>
</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Lemborexant.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <p>1. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Lemborexant+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Lemborexant: from PubMed.gov</ext-link></p>
        <p>2. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Lemborexant">Trials on Lemborexant: from ClinicalTrials.gov</ext-link></p>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
